Anavex Life Sciences (AVXL)
(Delayed Data from NSDQ)
$4.51 USD
+0.32 (7.64%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $4.51 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth D Momentum D VGM
Brokerage Reports
Anavex Life Sciences Corp. [AVXL]
Reports for Purchase
Showing records 61 - 80 ( 156 total )
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
ANAVEX3-71 Generates Positive Phase 1 Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Multiple Near-Term Data Catalysts; Fiscal 2021 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY: YE Results & Multiple Catalysts Set to Play Out
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Blarcamesine Alzheimer''s Phase 2b/3 Trial Cleared to Continue; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Balance Sheet Strength; Near-Term Clinical Milestones; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Alzheimer''s Disease Animal Model Data; Fragile X Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Blarcamesine Delivers Punch in Parkinson''s Disease; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Biomarker Data Correlates Closely With Efficacy; Raising PT to $39
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY: Biomarkers Continue to Correlate This Time, It?s Parkinson?s Disease Dementia Patients
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY: Biomarkers May be One of the Keys to Approval in Alzheimer?s Disease ? This Was Always the Plan at Anavex
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Mechanistic Elucidation in Alzheimer''s Disease; Raising PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Alzheimer''s Disease Phase 2b/3 Trial Enrollment Completion; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY: Alzheimer?s Pivotal Trial Exceeds Enrollment Target
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Notice of Allowance for Blarcamesine in Cardiac Dysfunction; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY: Reports the Second Quarter - $76M in Cash - A Rich Quarter
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Balance Sheet Strength; Multiple Data Catalysts; F2Q21 Financials; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY: DSMB Rett Syndrome Study Should Continue: No Change
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J